Clinical trial
Phase II Trial of Gleevec and Taxotere as a Combined Regimen for Advanced…
NCT00209079 · Emory University, Other · Terminated
Key facts
| NCT number | NCT00209079 |
|---|---|
| Title | Phase II Trial of Gleevec and Taxotere as a Combined Regimen for Advanced Gastric Adenocarcinoma |
| Official title | Phase II Trial of Gleevec (Imatinib Mesylate) and Taxotere (Docetaxel) as a Combined Regimen for Advanced Gastric Adenocarcinoma |
| Lead sponsor | Emory University, Other |
| Collaborators | Novartis Industry |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Gastric Adenocarcinoma |
| Intervention type | Drug |
| Interventions | Gleevec, Taxotere |
| Enrollment | 5 |
| Start date | Sep 1, 2004 |
| Primary completion | Apr 1, 2007 |
| Completion | Apr 1, 2007 |
| First posted | Sep 21, 2005 |
| Last update posted | Dec 31, 2007 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: